Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours

Trial Profile

A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs FP-1305 (Primary)
  • Indications Colorectal cancer; Liver cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms MATINS
  • Sponsors Faron Pharmaceuticals
  • Most Recent Events

    • 07 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 03 Dec 2018 According to a Faron Pharmaceuticals media release, company plans to conduct dose escalation part of the study in the Netherlands (Erasmus University Medical Center in Rotterdam), and plans to increase the number of sites during the cohort expansion stage. The Company is also preparing a US IND to expand the study to the USA during parts two and three of the the study.
    • 03 Dec 2018 According to a Faron Pharmaceuticals media release, CTA is also under review by the UK's regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA) for opening sites in the UK (the Royal Marsden Hospital in London and the Queen Elisabeth Hospital in Birmingham).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top